Roth Capital resumed coverage of Stereotaxis (STXS) with a Buy rating and $4 price target The firm believes the company is positioned for long-term revenue growth and profitability from continued adoption of its Robotic Magnetic Navigation technology along with “imminent” regulatory approvals and subsequent commercial launches of its product pipeline.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STXS:
- Stereotaxis announces EU launch, 510k submission for Synchrony system
- Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today
- Strategic Collaboration and Market Expansion Drive Buy Rating for Stereotaxis
- Stereotaxis, CardioFocus collaborate to advance robotic PFA technology
- Stereotaxis announces procedures using Genesis at Erasmus Medical Center